Warfarin + Apixaban
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-valvular Atrial Fibrillation
Conditions
Non-valvular Atrial Fibrillation
Trial Timeline
Jul 1, 2022 → Oct 19, 2022
NCT ID
NCT05438888About Warfarin + Apixaban
Warfarin + Apixaban is a pre-clinical stage product being developed by Pfizer for Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT05438888. Target conditions include Non-valvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05438888 | Pre-clinical | Completed |
| NCT04198844 | Pre-clinical | Withdrawn |
Competing Products
17 competing products in Non-valvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| DU-176b 15mg + DU-176b 30mg + DU-176b 60mg | Daiichi Sankyo | Phase 3 | 77 |
| Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin | Daiichi Sankyo | Approved | 85 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| AZD0837 + Aspirin | AstraZeneca | Phase 2 | 52 |
| Apixaban + Warfarin | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Approved | 84 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban(Xarelto,BAY 59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto,Bay 59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Warfarin | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY-597939) + VKAs | Bayer | Pre-clinical | 20 |
| Non-VKA Oral Anticoagulants (NOAC) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto_ BAY59-7939) | Bayer | Pre-clinical | 20 |
| Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) | Bayer | Pre-clinical | 20 |